ABSTRACT
Background: Handgrip strength (HGS) is an important parameter to assess the upper extremity muscular strength. Aims and Objectives: Aim of the study is to record HGS in healthy young males and to compare with fat mass (FM), fat-free mass, fat-free mass index, and to find out which is better correlated. Materials and Methods: A total of one hundred and fourteen first year male medical students of age between 17 and 22 years were taken as sample. Results: The correlation between fat free mass, fat free mass index with HGS was found to be extremely significant whereas correlation between FAT%, FM with HGS was not significant. Conclusion: Increase in lean body mass increases muscular strength as fat-free mass and fat-free mass index positively and significantly correlated with HGS.
ABSTRACT
The study was carried out to investigate the effect of panchakavya made from cow (PK-C) and buffalo (PK-B) products on urease and dehydrogenase activity and root yield of Ashwagandha and it revealed that soil application of PK-C @ 15% recorded the highest urease activity at both the stages of crop (85.24, 44.56 at flowering and harvest during rabi 2007-08 and 81.07, 35.50 μg of NH4 + released g-1 soil h-1 at flowering and harvest in kharif 2008). The highest dehydrogenase activity also noticed in the same treatment (91.05, 49.05 μg of TPF g-1 soil day-1 at flowering, harvest during rabi 2007-08 and 81.00,, 39.64 μg of TPF g-1 soil day-1 at flowering, harvest in kharif 2008) during both the years. The highest dry root yield was recorded with PK - C @ 5% - 4 sprays (290 and 280 kg ha-1 during both the years, respectively).
ABSTRACT
Recombinant activated factor VII (rFVIIa, NovoSeven) enhances haemostasis in individuals, with its predominant action limited to areas of injury, apparently without systemic activation of the coagulation cascade. rFVIIa is currently licensed in most countries worldwide, for its use in the treatment of bleeding episodes in patients with hemophilia and the presence of inhibitors. Recently in the European Union, rFVIIa, has been approved for use in congenital Factor VII deficiency and Glanzmann's thrombasthenia. Furthermore, a large number of case series studies and anecdotal evidences, from patients with different bleeding conditions, have now shown that rFVIIa is actually a very valuable general haemostatic agent. It has been reported to reduce bleeding in patients with liver disease, thrombocytopenia/thrombocytopathia, trauma, spontaneous intracerebral hemorrhage and in the reversal of anticoagulant overdosage or toxicity. A number of trials have been carried out, which have shown that it is a relatively safe and well tolerated drug with a few episodes of unwanted thrombosis.